ProCE Banner Activity

Dabrafenib + Trametinib Demonstrated Promising Activity in Pretreated BRAF V600E–Positive Advanced NSCLC

Slideset Download
Conference Coverage
Phase II study results suggest dabrafenib plus trametinib have meaningful antitumor activity, manageable safety profile in BRAF V600E–mutated NSCLC.

Released: June 03, 2015

Expiration: June 01, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation